Maus, Mate http://orcid.org/0000-0002-2128-2479
López-Polo, Vanessa http://orcid.org/0000-0001-6165-2510
Mateo, Lidia http://orcid.org/0000-0002-9076-4025
Lafarga, Miguel
Aguilera, Mònica http://orcid.org/0000-0003-0763-7947
De Lama, Eugenia
Meyer, Kathleen
Sola, Anna http://orcid.org/0000-0003-2379-9313
Lopez-Martinez, Cecilia http://orcid.org/0000-0001-7269-4126
López-Alonso, Ines
Guasch-Piqueras, Marc http://orcid.org/0000-0003-2392-2860
Hernandez-Gonzalez, Fernanda http://orcid.org/0000-0001-5113-4285
Chaib, Selim http://orcid.org/0000-0003-0497-2002
Rovira, Miguel http://orcid.org/0000-0002-1391-8465
Sanchez, Mayka http://orcid.org/0000-0002-6499-5989
Faner, Rosa
Agusti, Alvar http://orcid.org/0000-0003-3271-3788
Diéguez-Hurtado, Rodrigo
Ortega, Sagrario
Manonelles, Anna http://orcid.org/0000-0003-2456-388X
Engelhardt, Stefan http://orcid.org/0000-0001-5378-8661
Monteiro, Freddy http://orcid.org/0000-0002-9080-6715
Stephan-Otto Attolini, Camille http://orcid.org/0000-0001-8045-320X
Prats, Neus
Albaiceta, Guillermo http://orcid.org/0000-0002-9276-3253
Cruzado, Josep M. http://orcid.org/0000-0003-1388-8558
Serrano, Manuel http://orcid.org/0000-0001-7177-9312
Article History
Received: 28 July 2022
Accepted: 11 October 2023
First Online: 14 December 2023
Competing interests
: M. Serrano is a shareholder of Senolytic Therapeutics, Life Biosciences, Rejuveron Senescence Therapeutics and Altos Labs and is an advisor to Rejuveron Senescence Therapeutics and Altos Labs. M. Serrano has been a consultant, until the end of 2022, for Rejuveron Senescence Therapeutics and Altos Labs. The funders had no role in the study design, data collection and analysis, decision to publish or manuscript preparation. The remaining authors declare no competing interests.